Products
VIVJOA® (oteseconazole capsules) | Mycovia Pharmaceuticals, Inc.
Product description
VIVJOA® is the first FDA-approved therapy for recurrent vulvovaginal candidiasis (RVVC) in females who are not of reproductive potential. It’s an azole antifungal indicated to reduce the incidence of RVVC.